Neuropeptide Y and Sex Differences in Schizophrenia
Author Information
Author(s): Song Jia-Qi, Xin Wen, Yu Jian-Jin, Zhao Qing, Li Hong-Na, Chen Da-Chun
Primary Institution: Beijing Huilongguan Hospital, Beijing, China
Hypothesis
Is there any sex differences in the pathogeneses of schizophrenia related to Neuropeptide Y levels?
Conclusion
Neuropeptide Y plays a significant role in the pathogenesis of schizophrenia, with higher levels in male patients correlating with symptom severity, while this correlation is not observed in females.
Supporting Evidence
- Serum NPY levels were significantly higher in first-episode schizophrenia patients than in healthy controls.
- In male patients, NPY levels were positively correlated with the severity of symptoms.
- The interaction terms of NPY and sex were highly significant in relation to PANSS scores.
Takeaway
This study found that a substance called Neuropeptide Y is higher in men with schizophrenia and is linked to how severe their symptoms are, but this isn't the case for women.
Methodology
The study measured serum Neuropeptide Y levels in 115 first-episode schizophrenia patients and 58 healthy controls, using the Positive and Negative Symptoms Scale (PANSS) to evaluate symptom severity.
Potential Biases
The study's findings may be influenced by the differences in marital status between patient and control groups.
Limitations
Only serum NPY levels were measured, and the study did not find significant changes in NPY levels after treatment, suggesting a potential lag in response.
Participant Demographics
Patients were Han Chinese, aged 18-45, with first-episode schizophrenia.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website